Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
12 reports, 4 independent
Updated Sep 19
Gone quiet
- Reports
- 12
- Developments
- 4
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Stock price gains due to a potential regulatory catalyst.1 source
- FDA questioned statistical methods and benefit-risk assessment for Capricor Therapeutics, which is seeking approval and trading on the Nasdaq exchange.Sub-event
- Capricor Therapeutics modified its statistical analysis plan without obtaining prior approval from the FDA.Sub-event
Capricor Therapeutics seeks FDA approval for trials and lists on Nasdaq.1 source
Keep exploring
The entities involved
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.